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Obesity and Diabetes, the major cause for morbidity and mortality in United States raises 
a general curiosity regarding health care expenses when talked about treating them. Every year 
approximately 300,000 US adults die of reasons associated to obesity and diabetes, becoming the 
sixth leading cause of death. The prevalence of those diagnosed with diabetes witnessed an 
exponential curve in the last decade and for the year 2011 about 8.3% of the population in the 
US has been diagnosed with diabetes and it is predicted that in the year 2030 the prevalence of 
diabetes is to reach 4.4% globally. Type 2 diabetes is a condition, which develops when the body 
no longer makes enough insulin or when the insulin so produced does not work effectively. In 
reaction to the increase in obesity, treatments for obesity became more common especially the 
pharmacological treatments. Since this treatment also required one to change their lifestyle and 
food habits, bariatric surgeries were considered as an option to treat obesity and diabetes. A 
range of surgical procedures have been used to stimulate weight loss for obese patients. These 
procedures resulted in weight loss by restricting the size of the stomach (Gastric Banding) or 
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bypassing a portion of the intestine (Gastric Bypass). Roux-en-Y Gastric Bypass (RYGB) 
accomplishes weight loss during a combination of gastric restriction and malabsorption. 
Reduction of the stomach to a small gastric pouch results in feelings of satiety. The RYGB 
procedure has been performed regularly since the early 1980s; it was first performed 
laparoscopically in the early 1990s. Ileal interposition (IT) is a surgical procedure where a 
section of ileum is snipped and moved closer to the jejunum. It is said that the food takes just ten 
minutes to reach the ileum instead of an hour after this procedure. The ileum produces Glucagon 
like Peptide-1 (GLP-1) which helps in insulin secretion. Glucose is a key stimulator for 
mammals and is derived from the diet consumed, transferred from the circulation into the target 
cells. Glucose penetrates the eukaryotic cells through membrane associated carrier proteins, the 
   coupled glucose transporter (SGLT-1) and the glucose transporter (GLUT). These 
transporters are structurally and functionally distinct. The main research question was “are the 
receptors involved in glucose transport across the membrane (GLUT2 and SGLT1) important for 
Ileal Interposition”? With experiments like real time PCR (qPCR) and immunohistochemistry 
(IHC), we have observed the differences in the expression of these receptors with respect to the 
location and organ. Ileal interposition showed a significant difference (p<0.01) compared to 
sham-operated rats in the expression of GLUT2 in the gluconeogenic organs. The increased 
GLUT2 levels in ileal interposition may explain glucose sensitivity and these data emphasize the 
need for GLUT2 to maintain a positive glucose homeostasis and further study on 
SGLT1/GLUT2 influence on gluconeogenesis. 
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CHAPTER 1 
OBESITY AND DIABETES 
Introduction 
Last two decades have projected an increase in the prevalence of obesity in turn building 
grounds for type 2 diabetes. The graph of mobility and mortality has taken an exponential shape 
leaving diabetes in the undiagnosed state (Wee, Hamel, Huang, et al 2008). Obesity is medically 
expressed as excess fat deposition in the body, causing health issues (Lazar, et al 2005). Obesity 
is determined by a factor called Body Mass Index (BMI) which is calculated by dividing the 
weight in kilograms by the square of the height in meters (Ogden, Carroll, Flegal, et al 2006). 
According to World health Organization (WHO) the definition of overweight is a BMI of 25 
Kg/m²; BMI of 30 Kg/m² is called obesity and a BMI of 40 Kg/m² or higher is termed as extreme 
obesity and currently, the BMI requirement for the treatment of obesity is ≥40kg/m² (Ogden, 
Carroll, Flegal, Johnson et al 2002). Obesity and Overweight are associated to further cause 
arthritis, dyslipidemia, sleep apnea, depression, hypertension and type II diabetes (Flegal, 
Carroll, Kuczmarski, Johnson et al 1997).  
 
The International Diabetes Federation (IDF) predicted that in 2010, around 285 million 
people will be diagnosed with type 2 diabetes worldwide (International Diabetes Federation 
2010).The anticipated number of people to acquire type 2 diabetes                                                                                                                                                                                        
is likely to touch almost 450 million by 2030. Diabetes enforces a considerable health and 
economic burden and for the year 2007, in the US the cost of diabetes was amounted to be $200 
billion (Diabetes Statistics 2010). In United States, the prevalence of obesity is greater than 35% 
for the year 2008. Obesity is one of the reasons for a variety of other health issues which 
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includes diabetes, high blood pressure and cardiovascular diseases (Flegal, Ogden, Carroll, 
Curtin et al 2010). In the world, every year around 18 million people suffer from heart ailments 
having diabetes and high blood pressure as a major thrust factor. Diabetes is mounting as a 
universal health care crisis and it is anticipated that in the year 2030 about 370 million people 
worldwide will be suffering from this aliment (Hossain, Kawar, Nahas et al 2007). Type 2 
Diabetes brings not only problems related to high blood pressure but also insufficient and 
improper secretion of insulin leading to hepatic, adipose tissue, skeletal muscle glucose 
dysfunction (Sena, Bento, Pereira, Seica et al 2010).    
 
 
Origin of Weight loss Surgery 
Obesity management has become one of the prime factors as far as weight loss is 
concerned. Obesity can be treated by increasing physical activity, controlling diet and with 
therapies such as pharmacotherapy, behavioral therapy and hypnosis (Kim JJ et al 2003). 
Methods like diet and exercise with drug therapy can reduce glucose levels in the blood and 
keeps insulin secretion under control (Sena, Bento et al 2010). Pharmacological treatments like 
Exenatide and Metformin (FDA approved) used to treat obesity remained ineffective because the 
main treatment modalities still remain change in lifestyle and physical exercise (National 
Institute of Health and Clinical Excellence 2006).  
 
Surgical techniques brought beneficial effects into limelight; weight loss being the 
primary goal.  The first gastric bypass surgery was performed in 1967 and in 1991 National 
Institute of Health (NIH) recognized the criteria for bariatric surgery as BMI ≥40 Kg/m² and the 
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mean age of people getting the surgery done is around 16-64 years. In United States few 
commonly performed bariatric surgeries for treating obesity are Adjustable gastric banding, 
Sleeve gastrectomy and Roux-en-Y gastric bypass (Prachand et al 2011).  Studies in general 
have reported about 80% reductions in Type II Diabetes within weeks after gastric bypass 
(Pories WJ 1995; Busetto L 2011).  
 
With the resolution in diabetes, bariatric surgery also brings a change in the level of 
hormones like GIP, GLP-1, Ghrelin and PYY likely due to the re-routing of nutrients through the 
GI tract and causing a resultant hyper secretion of these hormones (Korner J et al 2009). In 
United States, to reduce the effects of morbidity and mortality, bariatric surgery plays a cost 
effective role. Patients with severe obesity and diabetes (BMI >35Kg/m²) are the largest 
population to get bariatric surgery (Ward M, Prachand V 2009).  The anti-diabetic effects of 
bariatric surgery with respect to weight loss is much higher than the involvement of lifestyle as 
result giving an improvement in glucose homeostasis (Pattou et al 2008). Bariatric surgery is 
now believed to be a positive way to resolve obesity and type 2 diabetes among surgeons but the 
means by which an improvement is seen in patients with diabetes after bariatric surgery is not 
clearly defined (Frachettia KJ et al 2009). 
 
Ileal Interposition (IT) Surgery 
As the statistics show an exponential curve in the number of bariatric surgeries being 
performed, it has also become a necessity that the allied morbidity and malabsorption is reduced. 
A novel surgical technique called ileal interposition only requires a part of ileum to be moved 
proximally into the jejunum (Koopmans H, Scalfani A et al 1982; Hari Kumar KVS et al 2009).  
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Ileal interposition when performed on rats shows that the lower intestine plays a critical 
role in metabolic improvement and improves glucose tolerance in diabetic model rats (Strader 
AD et al 2004, 2006 and 2008). Ileal interposition also has shown to bring on weight loss and 
progress the insulin signaling in diabetic and obese rat models. IT surgery basically is the 
rearrangement of a small segment of ileum to the proximal section within the jejunum (Strader 
AD et al 2008). This interposition of ileum results in an increase in the secretion of two 
important hormones Glucagon like peptide-1 (GLP-1) and Peptide YY (PYY) from L- cells. L-
cells are found throughout the lining of the GI tract containing regulatory peptide hormones 
(Shukla AP et al 2011).  
 
 
 
   
 
Figure 1.1: Ileal Interposition Surgery (a 10 cm segment of distal ileum is interposed 
within the jejunum and sutured using 7-0 silk. 
 
 
“Interposed” Ileum 
Ileal Anastomosis 
10cm ileum segment 
Cecum 
Duodenum 
Jejunum 
5 
 
Glucagon like Peptide (GLP-1) and Peptide YY (PYY) 
Glucagon like Peptide (GLP-1) is an incretin hormone that helps in increasing insulin 
levels intravenously. It is secreted by endocrine cells that are located in the epithelium of the 
small intestine located primarily within the ileum and colon of L cells. The incretin effect is 
attributed to two hormones, secreted from the intestine in response to the food ingestion one 
being GLP-1 and the other being Gastric Inhibitory Polypeptide (GIP). An elevation in the 
concentration of glucose in the lumen of the digestive tract acts as the trigger for GLP-1 
secretion (Eissele et al 1992). Intravenous delivery of glucose will not increase enteroendocrine 
secretion of GLP-1 since L-cells require direct contact with nutrients.  
GLP-1 secretion plays an important role in the regulation of postprandial glucose and diet 
control. (Tolhurst G et al 2008).  The major drawback for the use of GLP-1 in the clinical setting 
is its short biological half-life which is about 1.5–5 min. However, when GLP-1 is given 
constantly to type 2 diabetes, blood glucose is normalized and, more importantly, postprandial 
glucose excursions are also blunted (Hongxiang Hui, Loredana Farilla et al 2002).Gastric 
inhibitory polypeptide (GIP) is a 42 amino acid peptide hormone synthesized and secreted from 
K cells in the intestinal epithelium. The majority of intestinal K cells are located in the proximal 
duodenum. GIP secretion is mostly regulated by nutrients and is highly expressed in pancreatic 
islet alpha-cells and promotes insulin secretion (Fujita Y, Wideman RD et al 2010). GIP 
secretion does not get influenced by ileal interposition surgery since duodenum is not 
manipulated during the surgical procedure (Strader AD et al 2004). 
Peptide YY is associated with the pancreatic peptide family, has 18 of its 36 amino acids 
located in the same positions as pancreatic peptide. PYY is found in L cells of gastrointestinal 
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tract, especially in ileum and colon (Adrian TE et al 1985). The role of PYY has been known to 
restrain gastric emptying and acid secretion, also to decrease the stimulated pancreatic exocrine 
secretion and increase the intestinal transport time (Allen JM et al 1984). Recently it has been 
found that intravenous infusion of PYY indicates a possible therapeutic role in weight control in 
humans (Batterham RL et al 2003). 
Post Ileal Interposition, both GLP-1 and PYY are significantly elevated when compared to 
sham surgery, indicating the importance of ileum in glucose regulation and delayed gastric 
emptying. As an incretin GLP-1’s function on the beta cell is found to be consistent after 
physiological changes observed after ileal interposition (Strader AD et al 2008). On the whole 
delay in gastric emptying is associated with a drop in the amount of postprandial glucose 
entering the blood circulation. This condensed the disequilibrium between the swiftness of entry 
and exit of glucose from the circulation and thus reduced postprandial peak plasma glucose 
excursions by ~40%. When an additional amount of glucose is rapidly added to the plasma pool, 
the longer it takes to eliminate the supplementary glucose amounts (Gerich JE et al 2003).  
In recent times, it has been reported that once-daily injections of exendin-4 to diabetic 
mice accomplished enduring useful effects on blood-glucose concentration suggesting exendin-4 
as an option for treating type 2 diabetes (Greig NH et al 1999). 
 
Proopiomelanocortin (POMC), Agouti-related peptide (AgRP) and 
Neuropeptide Y (NPY) 
  
 POMC and AgRP neurons as the control device for energy homeostasis 
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Hypothalamic neurons have been studied in concern to the control of diverse body 
functions such as stress, sexual behavior and energy homeostasis (Schwartz, et al. 2000). The 
arcuate nucleus (Arc), positioned next to the third ventricle, and widely studied neuronal 
populations in the Arc are the propiomelanocortin (POMC) and agouti-related protein (AgRP)/ 
Neuropeptide Y (NPY) expressing neurons. In POMC neurons, the neuropeptide precursor 
POMC is cleaved to alpha melanocyte stimulating hormone (alpha-MSH), post secretion 
activates melanocortin 4 receptors (MC4 R) (Mountjoy, et al.1994; Wu, et al. 2002). 
 
On the other hand, neuropeptide Y (NPY) release by AgRP/NPY neurons has an 
orexigenic effect, mediated by a subtype of NPY receptors on downstream neurons. Agouti 
related protein (AgRP) directly blocks alpha-MSH mediated activation of the MC4R, thus 
slowing down alpha-MSH action (Yaswen et al. 1999; Gropp et al. 2005; Luquet et al. 2005).  
 
The GLUT2 Knockout Mice and Intestinal Gluconeogenesis 
 Subsequent to the entero-gastro anastomosis (EGA) procedure; a procedure similar to 
gastric bypass surgery in mice were duodenum and the proximal jejunum is excluded from the 
alimentary tract. It was found that it specifically reduced the food ingestion; increased insulin 
sensitivity while in the mice which received gastric banding procedure had a reduced intestinal 
gluconeogenesis when compared to the EGA procedure. All the EGA effects were removed in 
the GLUT2 knockout mice to grant positive consequence of EGA procedure over gastric banding 
(Troy S et al 2008). The laparoscopic gastric banding used universally to treat obesity is a purely 
restrictive bariatric procedure (Bo and Modalsli 1983). Decrease in the fat mass stimulated by 
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bariatric surgery has been normally acknowledged as the best elucidation for the control and 
turnaround of the diabetes mellitus (Buchwald et al 2004; Sjostrom et al 2004). However, it 
remains unclear whether Roux -en-Y gastric bypass (RYGBP) can get used to the insulin 
resistance and glucose tolerance rapidly (Pories 2004). 
 It is now quite clear that the intestine is more than just digestive system and especially the 
small intestine can generate glucose and discharge it into the portal blood in a process called 
‘intestinal gluconeogenesis’ (Mithieux 2005). This prospective characteristic of intestine has 
become meaningful through a variety of latest studies. The chief enzymes of gluconeogenesis are 
Glucose-6-phosphatase (GLc6Pase) and Phosphophoenolpyruvate (PCK1). Their mRNA is 
found in the small intestine in both humans and rats (Rajas et al 1999; Yanez et al 2003; 
Mithieux 2005).  
Intestinal gluconeogenesis basically takes place when GLc6Pase and PCK1 genes are 
stimulated during fasting, feeding high fat diet or during the occurrence of diabetes mellitus 
(Croset et al 2001, Mithieux et al 2004a and 2005). In addition to this it has been predicted that 
the intestine plays as a vital contributor to glucose production when the liver becomes 
underprovided (She et al 2003). The portal sensing of intestinal gluconeogenesis bring on a 
condition called hypophagia and infusion of glucose changes the entire body glucose disposal 
(Battezzati et al 2004).  
Gluconeogenesis  
 Gluconeogenesis is the biosynthesis of new glucose. Since glucose is a main energy 
source, the production of glucose from other metabolites is necessary for organs such as the 
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brain, erythrocytes and kidney medulla. The principal carbon skeletons used for gluconeogenesis 
are derivatives of pyruvate, lactate, glycerol, and the amino acids alanine and glutamine. The 
liver is the major location of gluconeogenesis and kidney also has an important organ in the 
gluconeogenic pathway. The gluconeogenic pathway is closely associated with the breakdown of 
glucose by glycolytic pathway. Gluconeogenesis and glycolysis share several enzymes and 
metabolic intermediates, but gluconeogenesis is not simply the reversal of glycolysis. 
 Lactate, Pyruvate, Amino acids and Glycerol are the central substrates of 
gluconeogenesis and with the help of few biochemical cycles, the liver helps converting these 
substrates into new glucose. Lactate is the one and only predominating source of carbon atoms 
for the synthesis of glucose through gluconeogenesis. During anaerobic glycolysis in the skeletal 
muscle, pyruvate is converted to lactate by the enzyme lactate dehydrogenase (LDH). When 
LDH is released into the blood stream, therefore transported to the liver where it gets converted 
into glucose. This newly formed glucose is then returned to the blood for the use by the muscle 
and other tissues as a source of energy. This cycle is called as Cori cycle.  
 Pyruvate, which is generally found in muscle and peripheral tissues, gets transaminated to 
alanine which is returned to the liver for gluconeogenesis. This cycle is called as glucose-alanine 
cycle. Its foremost function is to permit non-hepatic tissues to transport the amino acids to the 
liver for excretion as urea. Inside the liver, alanine is transformed into pyruvate and used as a 
substrate for gluconeogenesis. The amino nitrogen is converted to urea and thereby excreted by 
the kidneys. When glycogen level depletes in muscles and liver due to exertion and fasting, the 
catabolism of muscle proteins to amino acids donates the major source of carbon for the 
maintenance of glucose in the blood stream. 
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 The conversion of pyruvate to phosphoenolpyruvate (PEP) usually involves two 
mitochondrial enzymes. The first one is necessitated by an ATP catalyzed reaction of pyruvate 
carboxylase. This reaction helps in the formation of oxaloacetate. The second enzyme essentially 
helps in the conversion of pyruvate to PEP carboxykinase (PCK1). PCK1 needs a GTP in the 
decarboxylation of oxaloacetate to yield PEP. While pyruvate carboxylase adds in     into 
pyruvate, it is subsequently also released in the PCK1 reaction becoming the rate-controlling step 
of gluconeogenesis. 
 The next step in gluconeogenesis involves the conversion of Fructose-1, 6-bisphosphate 
to fructose -6-phosphate, which is the reverse of the rate limiting step of glycolysis. This reaction 
is catalyzed by fructose-1, 6-bisphosphatase. The final step in gluconeogenesis is the formation 
of glucose by means of Glucose-6-phosphate through the action of glucose-6-phosphatase. This 
reaction is simple hydrolysis similar to that of fructose-1, 6-bisphosphatase.  
The brain and skeletal muscle are deficient of the glucose-6-phosphate activity and 
therefore any gluconeogenesis that takes place in these non-hepatic tissues is not used for blood 
glucose supply. Even though liver plays a fundamental role in the maintenance of blood glucose 
homeostasis and is the major site for gluconeogenesis, under hepatic failure conditions if the 
level of glucose in the blood goes down then the kidney provides glucose. This is known as 
Renal Gluconeogenesis wherein in the renal cortex the glutamine is the favored substance for 
gluconeogenesis. 
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Gluconeogenesis Pathway (Schematic Representation) 
 
 
 
  
 
 
          
 
         
 
           
 
        
Figure 1.2: Illustration of the biochemical pathway called Gluconeogenesis  
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Glucose Homeostasis and Regulation 
Glucose is a monosaccharide and is an important source of energy, facilitating the 
generation of ATP following glycolysis (Cryer PE et al 1992). Glucose is stored in the body, 
notably in the liver, as glycogen. Blood-glucose levels are primarily controlled and regulated by 
two hormones, insulin and glucagon (Aronoff SL et al 2004). Homeostasis is defined as the 
tendency to maintain the equilibrium of different internal systems by using various biochemical 
and physical processes. For example: the body's attempt to regulate internal body temperature 
and normal blood pressure (DeFronzo et al 1988).  
Glucose homeostasis or the blood glucose regulation depends on the balance and 
interactions between insulin and glucagon in order to maintain a normal and steady blood 
glucose level (DeFronzo et al 1988). During the phases like starvation and intense exercise, 
glucose is also produced from non-carbohydrate precursors (pyruvate, glycerol) in a process 
called gluconeogenesis. An interruption in glucose homeostasis is universally studied in the state 
of diabetes mellitus, a metabolic syndrome in which patients do not make enough insulin (Gerich 
et al 1993).  
Insulin is generated in the beta-cells of pancreas in the reaction to an increase in blood 
glucose following a meal. The key function of insulin is to oppose the action of the hormones 
responsible for creating hyperglycemia and to maintain lower levels of blood glucose. 
Conversely, during hypoglycemia, the alpha-cells of the pancreatic islets of Langerhans produce 
glucagon. It is the primary hormone; in charge for maintaining plasma glucose at proper levels 
during phases of its chief requirements. This hormone counters the actions of insulin by 
stimulating hepatic glucose production (Gerich et al 1993; Cryer et al 2002).  
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Glucose Transporter Family 
 Glucose being the main substrate for energy, it plays a vital role in the metabolism and 
cellular homeostasis in eukaryotes. Most of the cells usually depend on glucose, which needs to 
be continuously supplied to them to produce ATP (Gould GW et al 1993; Joost H-G et al 1994). 
Glucose homeostasis and regulation takes place by its production in liver, tissue expenditure and 
its absorption in the small intestine. The brain is one such example of a tissue where it requires 
glucose on regular basis. Low concentrations blood glucose generally leads to cell damage and 
dizziness whereas higher concentration of glucose in the blood can result in type-2 diabetes and 
renal failure (Kaiser N et al 2003). Hydrophilic molecules are basically are impermeable and 
cannot pass through the plasma membrane; this is the main reason why glucose needs to be 
transported across the plasma membrane. The allied carrier protein for such impermeable 
molecules is known as the glucose transporters. Principally, there are two categories of 
transporters which mediate glucose and other sugars across the lipid bilayer: a     coupled 
carrier system known as Sodium dependent Glucose Transporter (SGLT) and the other being the 
facilitative glucose transporter called the GLUT family (Bell GI et al 1990; Carruthers A et al 
1990). 
 
 SGLT or Sodium dependent Glucose Transporter’s basically are the members of SGLT1 
(Solute Carrier) gene family of glucose transporter found in the small intestine and kidney. Its 
main function is to pump the Na⁺/K⁺ ATPase on the basolateral membrane which in turn leads to 
a downhill sodium gradient within the cell. The SGLT proteins use the energy from this downhill 
sodium gradient to transport glucose across the apical membrane against an uphill glucose 
gradient. This family of proteins is further divided into SGLT1, SGLT2 and SGLT3. Together 
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they are known as symporters or co-transporters, because both sodium and glucose are 
transported in the same direction across the membrane by an active transport mechanism. (Jung 
H et al 1998; Wegener C et al 2000; Turk E et al 1997).  
  
 The SGLT1 transporter’s expression is primarily seen in kidney, heart and intestine. The 
symporter outwards the concentrated glucose in the cell through the basolateral membrane with 
the help of facilitated GLUT-proteins. SGLT1 is a sodium-glucose symporter with high affinity 
and low capacity; possessing a ratio of 2:1 for sodium to glucose (Wright EM et al 2001). 
  
 The SGLT2 transporters expression is highly observed in kidney where it mediates the 
absorption of high volumes of the filtered glucose in the proximal convoluted tubule. This 
transporter possesses a ratio of 1:1 for sodium to glucose (Wright EM et al 2001). The SGLT3 is 
a glucose sensitive ion channel which does not transport glucose like the other two transporters.  
It basically generates information to the cell about the glucose concentration present outside 
straight through membrane potential (Diez-Sampedro A et al 2003). It is mainly detected in liver, 
spleen, intestine muscle and kidney (Kong CT et al 1993). 
 
 The GLUT family consists of 14 members which are subdivided into three with respect to 
their characteristics (Joost H-G et al 2001). The members of GLUT family reveal prominent 
tissue specific expression (Gould GW et al 1993; Kahn BB et al 1992). They normally vary in 
their functional characteristics as some of these members have functions which are modified by 
the regulated rearrangement of proteins flanked by the cell membrane and the intracellular 
compartments. The functions for most of the GLUT family are now known and their difference 
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in characteristic allows regulation in the glucose uptake and the gene encoding is called as Slc2a 
(Joost H-G et al 2001).  
 
 
                                  Schematic of the GLUT Family 
 
 
  
 
 
 
Figure 1.3: Classification of the GLUT FAMILY   
 
 
 The class I glucose transporters includes Slc2a1 to Slc2a4 and the very recently 
discovered Slc2a14. The GLUT family uses facilitative diffusion (spontaneous passage of 
molecules or ions across the membrane passing through specific transmembrane integral 
proteins) in order to transport glucose across the cell membrane. The universally expressed 
Slc2a1 has basically responsible for supplying cells with glucose and mostly show its expression 
in the erythrocytes and brain (Mueckler et al 1985). GLUT2 is a low affinity, high capacity 
glucose transporter with predominant expression in the pancreatic beta cells, liver, basolateral 
membrane of the small intestine and kidney (Fukumoto H et al 1988). Normally, the activity of 
THE GLUT 
CLASS I 
GLUT1, GLUT2, GLUT3, 
GLUT4 and GLUT14 
CLASS II 
GLUT5, GLUT7, GLUT9 
and GLUT11 
 
CLASS III 
GLUT6, GLUT8, 
GLUT10, GLUT12 and 
HMIT 
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this transporter depends highly on the blood glucose concentration and is also known for 
transporting fructose apart from glucose itself (Uldry M et al 2002).  
 
GLUT3 and GLUT4 is yet again a high affinity glucose transporter with high expression 
in brain, adipose tissue and skeletal muscle. Insulin kindles the translocation of GLUT4 from 
intracellular to plasma membrane, consequential in an immense 10 to 20 fold increase in the 
glucose transporter activity. In skeletal muscle, the translocation of this transporter is stimulated 
by hypoxia and muscle contraction (Kayano T et al 1988; Fukumoto H et al 1989). Slc2a14 is 
exclusively found in testis (Wu X et al 2002). 
  
The class II glucose transporter includes the fructose transporter Slc2a5 and three other 
associated proteins Slc2a7, Slc2a9 and Slc2a11. Slc2a5 is vastly expressed in the kidney, testis 
and small intestine. Slc2a5 is in charge for the uptake of fructose in tissues and doesn’t show 
signs of any glucose transport activity (Kayano T et al 1990).  Slc2a7 is a high affinity 
transporter, detected in small intestine, prostate and testis. It is chiefly expressed in brush border 
membranes and enterocytes (LI Q et al 2004). Slc2a9 is mostly expressed in liver and kidney 
where as small intestine shows lower levels of expression (Phay JE et al 2000). Slc2a11 is 
predominately expressed in the kidney, pancreas, and placenta; also displays a restrained 
expression in the heart and skeletal muscle (Gaster M et al 2004).  
 
 The class III glucose transporter includes Slc2a6, Slc2a8, Slc2a10, Slc2a12 and HMIT. 
The low affinity transporter Slc2a6 is chiefly observed in the spleen, brain and peripheral 
leukocytes (Doege H et al 2000). Slc2a8 is a high affinity transporter whose activity is 
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exclusively inhibited by the D-fructose and D-galactose, indicating Slc2a8 being a 
multifunctional transporter. It is mainly expressed in the testis and lower levels detected in 
insulin sensitive tissues. Slc2a8 might also take part in the glucose uptake of adipocytes; its 
expression was found to be synchronized by the metabolism of the cells (Carayannopoulos MO 
et al 2000). Slc2a10 is highly seen in liver and pancreas; the SLC2a10 gene was earlier mapped 
to a section that was allied with type 2 diabetes (Mc Vie-Wylie AJ et al 2001). Slc2a12 is 
remarkably expressed in heart and prostate and shows glucose transporter activity when 
expressed in X. laevis oocytes (Macheda ML et al 2002). The    coupled myo-inositol 
transporter (HMIT) is expressed in the brain; in particular HMIT transports myo-inositol but 
generally lacks glucose transport activity (Uldry M et al 2001).  
 
 
The interface of SGLT1 and GLUT2 before, between and after a meal 
 
 Site of GLUT2 and SGLT1 
 Regulation of GLUT2 translocation was initially illustrated at the apical membrane of the 
enterocytes of rats and the physiological significance of this mechanism was swiftly made 
conventional (Kellett GL, Helliwell PA et al 2000; Gouyon F et al 2003). As a matter of fact, 
glucose, fructose and galactose being the major sugars in the human diet, are readily taken up 
from the lumen to be transferred into the blood circulation through enterocytes (Wright EM et al 
2003).  
Though the lower levels of sugar like glucose and galactose between the meals are taken 
up at the apical membrane by SGLT1, a Na/glucose cotransporter; GLUT5, a facilitative 
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transporter readily takes up any available fructose molecules; mutually presenting a high affinity 
for sugars. If the concentration is low in the intestinal lumen than in the blood stream, glucose 
can be taken up by SGLT1 and transport it against the glucose concentration gradient. SGLT1 
makes use of the energy of the sodium electrochemical gradient sustained by the basolateral Na-
K-ATPase activity at the expenditure of metabolic energy (Wright EM et al 2003). The 
subsequent transport stride at the basolateral membrane is guaranteed by GLUT2, which 
transports glucose, fructose and galactose out of the enterocyte to the blood stream. If the meal 
restrains sugars exceeding SGLT1 and GLUT5 saturating concentrations, unsaturated GLUT2 is 
rapidly translocated to the apical membrane. Higher concentrations of sugars can thus be taken 
up from the lumen within few minutes of sugar intake (Gould GW et al 1991; Gouyon F et al 
2003).  
Subsequently GLUT2 is internalized by the means of insulin action (Tobin V et al 2008). 
GLUT2 functions in the intestine as a transport protein which is able to adjust with the capacity 
of sugar transport with respect to the luminal concentration of glucose (Kellett GL et al 2008). 
GLUT2 internalization by insulin therefore makes up the means to limit blood-glucose 
excursions, a principal action of the hormone.  
 
Remarkably, this regulation mechanism explains issues related to glucose absorption of 
sugar rich meals which were unclear so far. The apical translocation of GLUT2 in enterocytes is 
also harmonized by stress, corticoids and glucagon like peptide-2 (GLP-2), an enteroendocrine 
hormone (Kellett GL et al 2005). The apical translocation is not restricted to intestinal cells, in 
kidney reabsorbing cells, the epithelial transport sugars is similar to that in the intestinal cells. 
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Regulated GLUT2 apical translocation is now believed to be as a characteristic attribute of 
monocellular epithelial cells (Marks J et al 2003).   
 
 
 
 
  
 
  
 
 
Figure 1.4: Regulated translocation of GLUT2 and SGLT1 with respect to meal consumption  
 
 
 Regulation of sugar absorption before and after a meal 
Before a meal, the concentration of glucose in the lumen is a lot less than 5mmol/l in the 
plasma. Any glucose is quickly detained by SGLT1, which is known as the ideal for this 
rationale. SGLT1 is a low-capacity, high-affinity transporter and the only transporter proficient 
of transporting glucose against the concentration gradient. GLUT2 is a high-capacity, low-
affinity facilitative transporter that equilibrates glucose between the plasma and enterocyte. 
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 Consequently, at the time when the glucose level is modest in the lumen before a meal, 
GLUT2 is very low at the apical membrane and the basolateral GLUT2 functions in the reverse 
path to supply glucose from the blood and retains the energy necessities of enterocytes. Even 
when there is slight amount of glucose in the lumen before a meal, there might be some GLUT2 
at the apical membrane in vivo and this apical GLUT2 may lead to vast glucose secretion, as the 
gradient is downhill from plasma to lumen. This situation is controlled or avoided if the apical 
GLUT2 is reduced at low luminal glucose concentrations and is lost completely after an 
overnight fast.    
  
After a meal, the preliminary digestion products of elevated glycemic index 
carbohydrates, mainly disaccharides reach the apical membrane of the jejunum within 30 
minutes; are promptly hydrolyzed by membrane bound hydrolyses to generate a high effective 
glucose concentration on the peripheral apical membrane. As the concentration of free glucose 
adds up, the primary transport across the apical membrane occurs through SGLT1.  
 
This results in the rapid activation of apical GLUT2 previously in the membrane and 
additional inclusion of GLUT2 into the apical membrane from the intracellular vesicles 
originating the membrane. Apical GLUT2 is the present major pathway for absorption. As the 
glucose is absorbed and its concentration in the lumen cascades, the entire signaling system is 
reversed so that GLUT2 is inactivated and travels away from the apical membrane to re-establish 
the location before a meal.  
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Figure 1.5: The apical GLUT2 model illustrating glucose absorption before and after a meal. 
GLUT2 and SGLT1collectively account for total glucose absorption. 
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CHAPTER 2 
METHODS AND MATERIALS 
General Hypotheses and Experimental Aims 
Hypotheses:  
1. GLUT2 (primary glucose GI transporter) may be required for glycemic improvement 
following ileal interposition.  
2. Expression of SGLT1 in gluconeogenic organs (liver, kidney, intestine) may show the 
importance of SGLT1/GLUT2 channel required to control postprandial glucose. 
3. Hypothalamic genes known to regulate glucose homeostasis may be altered in rats with       
improved glucose tolerance following ileal interposition.  
 
Aim I:  
Determine the expression of SGLT1 and GLUT2 receptor in gluconeogenic organs using qPCR 
following sham and ileal interposition surgery. 
Aim II: 
Determine the protein expression of GLUT2 in all sections of the small intestine and pancreas 
using Immunohistochemistry. 
Aim III: 
Determine the expression of mRNA for POMC, AgRP and NPY in the hypothalamus of rats 
following sham and ileal interposition surgery.  
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Animals 
 
   Male Long Evans Rats (Harlan, Indianapolis, IN) were individually housed and 
maintained on a 12:12 light dark cycle. All procedures have been approved by the Institutional 
Animal Care and use Committee at Southern Illinois University Carbondale. 
 
Ileal Transposition 
  Normal non-diabetic male Long Evans Rats (Harlan) weighing 490-600g were 
anesthetized and maintained during the surgery with 2-4% Isoflurane. An incision, 
approximately 3 cm, was made through the skin and muscle just below the stomach. Once the 
small intestine was located with forceps, a 10cm segment is snipped from the ileum and is 
moved within the upper jejunum. Anastomosis was done to close the ends of the snipped 
segments using the surgical suture (7-0 Silk, Ethicon). Interrupted sutures were used to close the 
muscle skin layers (4-0 Silk, Ethicon). For sham surgery, rats were incised as previously 
indicated and the small intestine was located with forceps and three cuts were made at the same 
locations as the interposition procedure following re-anastomosis. Rats were weighed weekly to 
examine the post surgical changes in the body weight gain.  
 
Tissue Collection  
  6 months subsequent to surgical procedure, the rats were fasted overnight, final body 
weights recorded and were subjected to deep anesthesia with     followed by decapitation. 
Organs such as Liver, Pancreas, Hypothalamus, Kidney and segments of intestine were stored in 
RNA Later (a reagent used for RNA stabilization for later isolation; Ambion Qiagen, Valencia, 
CA)  for qPCR. Section of Pancreas and intestinal segments were fixed in Bouin’s solution for 
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Immunohistochemistry. Rats were divided into two groups with respect to the surgery they had 
received. Ileal Interposition group (n=8) and Sham group (n=9). 
 
RNA Isolation and cDNA Preparation 
  TriReagent was used to isolate RNA according to the protocol by MRC (Cincinnati, OH), 
1-bromo-3-chloropropane (BCP) for phase separation and isopropanol was used for RNA 
precipitation and finally quantified using spectrophotometry. Equal concentrations of RNA per 
sample were reverse transcribed using Superscript III enzyme kit (Quanta Kit). 
 
 Real Time PCR 
   cDNA, water and Mastermix of Quanta SYBR green fastmix and forward and reverse 
primers were loaded in a 96-well PCR plate in triplicates. SYBR 490 flourophore quantitative 
real time PCR was performed using the Biorad My IQ real time PCR system. The ribosomal 
gene, L32 was used as the housekeeping gene because its expression has not been shown to be 
affected by dietary or appetite related treatments. The average of the two closest     for the 
housekeeping gene and each gene of interest was used to calculate the        (Livak and 
Schmittgen 2001). Primers were designed using the website Primer3 (Figure 2.1) 
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Gene Primer Sequence 
L32 Forward  CAG ACG CAC CAT CGA AGT TA 
Reverse   AGC CAC AAA GGA CGT GTT TC 
Slc2a2 Forward  CGA CAC CAG ACG CCT GGG AAG 
Reverse  ACG AGG CGA CCA TTC CGC CTA  
SGLT1 Forward  TCC CCT CCC TCG GGG CTG AT 
Reverse  CGA CGA GTC CCT CCG GCT CA 
PCK1 Forward  AGC TAG GAG CAA ACC AGC AA 
Reverse  GAC CTC GAA GTG GAA CCA AA 
Preproglucagon Forward  GCT TGG CTG GTG AAA GGC CGA 
Reverse  GCA TGT CTG CGC CCA AGT TCC T 
PYY Forward  GGA GCT GAG CCG CTA CTA TG 
Reverse  TCT CGC TGT CGT CTG TGA AG 
POMC Forward  GGG AGG CGA CGG AGG AGA AA 
Reverse   CGG GGA CAG AGC TCA GCG TA 
AgRP Forward  TTC CCA GAG TTC TCA GGT CT 
Reverse   ATC TAG CAC CTC TGC CAA A 
 
Figure 2.1: Primer Sequence 
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Immunohistochemistry 
Segments of intestine and pancreas were fixed in bouin’s solution and were sliced at 
5µm. The sections were subjected to Antigen Retrival following rinse with tris buffer saline 
(TBS) without triton X-100 for pancreatic sections and with triton (0.1% triton X-100) for 
Intestinal sections. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide 
with methanol. Sections were then transferred to the primary antibody reactions for, GLUT2 
(1:50 dilution factor for Intestinal Segments and 1:100 dilution factor for Pancreas; Santa Cruz 
Biotechnology, Santa Cruz, CA) for 1 hour in room temperature. Sections were then incubated in 
a humidified chamber for 18 hours at 4°C on a rotator so that the primary antibody reacts well on 
the section. On the next day, the sections were incubated in the goat anti rabbit secondary 
antibody (1:600; Vector Labs, Burlingame, CA) for 45 minutes followed by 30 minute 
incubation with Avidin-Biotin Complex (ABC; Vector Labs, Burlingame, CA) and lastly an 8 
minute incubation in the chromate 3, 3-Diaminobenzidine (DAB). Sections were later collected 
and slide mounted to counter-staining with hematoxylin for 2 minutes and brought through an 
alcohol series before mounting. Sections were mounted and covered slipped for further use. 
Pictures of the sections were taken using 10X and 20X objective lens, bright field microscope. 
 
Statistical Analysis  
    Real time PCR data were analyzed with one-way ANOVA with post-hoc test called the 
Newman-Keuls Multiple comparison test and student’s t-test was used to determine the 
significance between the two surgical procedures.  
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CHAPTER 3 
GLUCOSE TRANSPORTER-2 (GLUT2) 
 
Introduction 
 The increase in the prevalence of type 2 diabetes has a close relationship with the rise in 
obesity. For about 90% of the type 2 diabetes, the origin is excess weight and about 200 million 
people worldwide have impaired glucose tolerance due to obesity and the allied metabolic 
syndrome (Hossain P et al 2007).  The number of bariatric surgery achieved yearly in United 
States for treating obesity has increased by 10 fold since the 1990s (Prachand VN et al 2011).  
 
Numerous case studies have shown that the benefits of bariatric surgery are beyond 
improving hyperglycemia and cardiovascular risks. The metabolic mechanisms primarily 
involved in improving glycemic control after bariatric surgeries have been partially explained. 
(Shukla AP et al 2011). Ileal interposition (IT) is a surgical model that separates the effects of 
increasing release of unabsorbed nutrients to the lower intestinal tract (Cummings BP et al 
2010). IT surgery has revealed to stimulate weight loss and improve insulin signaling in obese 
and diabetic models (Strader AD et al 2009).  
 
In the period of 1970s, several gut hormones like GLP-1 were identified which was 
renowned as an important contributor towards the continuance of glucose homeostasis (Cooper 
GJS et al 1987). Incretin hormones take part in helping regulate the glucose manifestation and in 
enhancing insulin secretion. GIP and GLP-1 both are stimulated by ingestion of food, but GLP-1 
is more physiologically important hormone. GLP-1 regulates gastric emptying by slowing the 
delivery of nutrients from the stomach to the small intestine (Holst JJ et al 1994). 
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Glucose is the major source of energy and is captivated across the small intestine by Na⁺- 
dependent active transport through the sodium dependent glucose transporter, SGLT1. It is less 
widely known that there is also a diffusive mechanism of glucose absorption, which can be quite 
a lot of times superior to the active pathway (Kellett et al 2008). Secondary active transport of 
glucose across the enterocyte apical membrane through SGLT1 is driven by a downhill gradient 
of Na⁺, upholder by the basolateral Na⁺/K⁺ ATPase. Once in the enterocyte, glucose crosses the 
basolateral membrane into the blood stream via the facilitative transporter called GLUT2 (Crane 
RK 1962). 
 
Hypothesis and Specific aim 
 
GLUT2 which is a primary glucose GI transporter may be required for glycemic 
improvement following ileal interposition. Therefore, determine the expression of GLUT2 
receptor in gluconeogenic organs using qPCR following sham and ileal interposition surgery. 
  
 
Methods and Materials 
 
Non-diabetic male Long Evan’s rats (Harlan, Indianapolis, IN) chow fed, fasted 
overnight and was anesthetized with isoflurane gas and received either a sham surgery or ileal 
interposition surgery. Following a period of 6 months after the surgeries, the rats were 
euthanized and various tissues were collected for different experiments. Brains were rapidly 
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removed and Gluconeogenic organs (Liver, Small intestine and Kidney), pancreas were placed in 
RNA later and stored at 4°C and then at -80°C until RNA were isolated. Hypothalami were 
dissected from the brains. GLUT2 expression in these organs was quantified using qPCR and 
compared to the housekeeping gene L32. Data were subjected to a one-way analysis of variance 
and Newman-Keuls Multiple Comparison test was used with respect to the surgery received.  
 
 
Results 
 
 The expression of GLUT2 mRNA (% change relative to L32) in the ileal interposition 
resulted in a 8 fold increase in the “interposed ileum” segment when compared to the sham 
surgery within the intestine (one-way ANOVA; p<0.01, Figure 3.1). GLUT2 mRNA (% change 
relative to L32) expression in the liver remained unchanged between the two surgical groups, 
suggesting no change in the expression of the receptor in the major organ for gluconeogenesis 
(Student’s t-test; p>0.05, Figure 3.2). In kidney, the GLUT2 mRNA (% change relative to L32) 
expression again remained unaffected in both the surgical groups and displayed a 50% reduction 
in the ileal interposition group (Student’s t-test; p>0.05, Figure 3.3).  
 
Within the pancreas, the interposition group exhibited a 30% reduction in the GLUT2 
mRNA (% change relative to L32) compared to sham group and demonstrate no significant 
difference between the two surgical groups (Unpaired t-test; p>0.05, Figure 3.4). In the case of 
hypothalamus, the interposition group exhibited almost 50% reduction in the GLUT2 mRNA (% 
change relative to L32) compared to sham group and show no significant difference between the 
two surgical groups (Unpaired t-test; p>0.05, Figure 3.5). 
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The expression of PCK1 mRNA (% change relative to L32) in the “interposed ileum” 
segment increased by 3 folds when compared to sham group within the intestine, whereas the 
colon displayed a significant difference in the interposition group compared to the sham group 
(one-way ANOVA; p<0.05, Figure 3.6) In the sham group, jejunum was insignificantly different 
when compared to the jejunum of interposition group (one-way ANOVA; p>0.05, Figure 3.6).  
 
In kidney, the PCK1 mRNA (% change relative to L32) expression viewed 70% 
reduction in the interposition group when compared to the sham, reflecting an insignificant 
difference between both the surgical groups (Student’s t-test; p<0.05, Figure 3.7). Within the 
pancreas, the interposition group exhibited a 1% increase in the PCK1 mRNA (% change relative 
to L32) compared to sham group and demonstrated no significant difference between the two 
surgical groups (Unpaired t-test; p>0.05, Figure 3.8). PCK1 mRNA (% change relative to L32) 
expression in the liver remained unchanged between the two surgical groups, suggesting no 
change in the expression of the receptor in the major organ for gluconeogenesis (Student’s t-test; 
p>0.05, Figure 3.9).  
 
The expression of PYY mRNA (% change relative to L32) in the interposition resulted in 
a 5 fold increase in the remnant ileum segment when compared the sham ileum, while the colon 
displayed a 5 fold increase in comparison to the duodenum and jejunum in the sham (one-way 
ANOVA; p<0.0001, Figure 3.10) In the interposition group, both duodenum and jejunum 
observed an significant difference when compared to the colon with the interposition group (one-
way ANOVA; p<0.05, Figure 3.10).  
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PYY mRNA (% change relative to L32) expression in the liver remained unchanged 
between the two surgical groups, suggesting no change in the expression of the receptor in the 
major organ for gluconeogenesis (Student’s t-test; p>0.05, Figure 3.11). 
 
Discussion 
 A previous GLUT2 study on diabetic rats in our lab showed significant difference 
between the sham and interposition group within the intestine. In this present study, the same 
affects as that in the diabetic rats were seen in the non-diabetic rats too. The interposed ileum is 
said to be “jejunalized” meaning that the interposed ileum takes up the functions of jejunum 
since the portion of ileum is placed next to jejunum. In addition, some studies have also 
described GLUT2 genes being expressed in rat jejunum and that in the jejunum of acute diabetic 
rats, the level of GLUT2 mRNA changed in parallel to d-glucose transport activity. Numerous 
studies have also shown that the transport capacity of gluconeogenic organs is altered by a 
variety of conditions such as dietary restrictions. This explains the insignificant results in the 
present study for liver and kidney since the rats were fasted overnight (16 hours) due to which 
the possibility of the glucose transport activity getting altered rises.  
 Troy et al study conducted in 2008 demonstrated that the GLUT2 knockout mice after the 
entero-gastro anastomosis (EGA) procedure failed to reduce their food intake and to improve 
their glucose tolerance and insulin sensitivity. The mice had steady food consumption before the 
EGA procedure and afterwards, increased their consumption and body weight. In contrast, the 
wild types (C57BI6) improved their % basal glucose measured after the oral glucose tolerance 
test (OGTT) but there was no significant change in glucose tolerance observed in case of GLUT2 
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knockout mice. The outcome of this study suggested that GLUT2 is essential for the regulation 
of the food intake and metabolic adaptation after the EGA procedure. 
An augmented rate of glucose utilization is a well recognized attribute coupled with the 
growth of a cell (Burk et al 1967; Singh et al 1974). Thus, extensively it is observed that the 
alteration of many cell types is escorted by prominent rates of glucose transport (Birnbaum et al 
1987; Flier et al 1987) and enhanced activity of the glycolytic enzymes like pyruvate kinase 
(Pedersen 1978; Hennipman et al 1988). In the kidney, the low-affinity glucose transporter 
(GLUT2) is found only in the proximal convoluted tubule (Thorens et al 1990) and takes part in 
glucose reabsorption from the glomerular filtrate, where as the high-affinity transporter (GLUT1) 
is expressed at different segments of renal tubular system and appears to be responsible for basal 
glucose uptake (Thorens et al 1990). It is found in several studies that increased glycolytic 
activity and reduced GLUT2 expression is found in the kidney (Young Soo Ahn 1992). 
 Observations from various other studies also states that GLUT2 is not detectable at the 
brush border membranes (BBM) of proximal tubules from rats after an overnight fast, suggesting 
that the protein is rapidly transferred in and out of the BBM in the reaction to changes in plasma 
or luminal glucose concentrations. The fact that GLUT2 has not been localized previously to this 
membrane might be because this transportation process is both rapid and dependent on ambient 
glucose concentrations (Larkins & Dunlop, 1992; Wolf & Thaiss, 1995; Nishikawa et al 2000). 
 
Overnight fasting completely abolishes the increase in GLUT2 expression, yet only has a 
little effect on the levels of GLUT5 (fructose transporter). These findings imply that GLUT2 is 
responsible for the improved glucose uptake seen during diabetes, with raised levels of glucose 
in the plasma or tubular fluid being the stimulus to increased GLUT2 expression. The 
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inconsistent increase in GLUT2 expression at the BBM in relation to the degree of stimulation of 
glucose transport suggests that hyperglycaemia also affects the intrinsic activity of this 
transporter. Indeed, changes in the activity of GLUT2 protein have been reported for the 
intestinal BBM in response to altered luminal glucose concentration (Kellett & Helliwell, 2000) 
and systemic infusion of glucagon-like peptide 2 (Au et al 2002). In the pancreas, GLUT2 
expression however is described only in the beta cells, where it may be essential in their glucose 
sensing function (Thorens B 1990).  
  
In the brain, certain neurons emerge subjected to any kind of modifications in the local or 
plasma glucose concentration. The modifications in the electrical activity of these neurons 
perhaps depend on the subsistence of the glucose sensors, which might be one of the glucose 
transporters illustrated so far. In an old study, it was demonstrated, using the qPCR, that GLUT 2 
mRNAs are present in a limited number of brain nuclei, including the motor nucleus of the vagus 
and the paraventricular hypothalamic nucleus. The localization of GLUT2 in regions in the past 
where associated with feeding behavior, supports an indirect role for GLUT2 in glucose sensing 
in the brain (Leloup C et al 1994). 
PCK1 is mostly expressed in liver, kidney and adipose tissue. The blood glucose level is 
maintained inside distinct confines due to the specific regulation of PCK1 gene expression. To 
highlight the significance of PCK1 in glucose homeostasis over expression of this enzyme in 
mice resulted in type 2 diabetes mellitus. PCK1 is controlled by two separate hormonal 
mechanisms. In the present study, we observed insignificant expression of PCK1 in the 
interposition group and this was expected since the experimental rats were non-diabetic. 
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PYY is found in L cells of the GI tract especially in ileum and colon. It is secreted by the 
neuroendocrine cells in the ileum and colon in reaction to meal consumption and it is said to 
reduce appetite. PYY works by slowing the gastric emptying; hence, it enhances the competence 
of digestion and nutrients absorption after a meal (Liu C et al 1996). A little amount (~10%) of 
PYY is said to be found in the stomach, duodenum and jejunum (Taylor IL et al 1985). 
Concentration of PYY in the blood circulation increases postprandial and decreases in the fasting 
state (Murphy KG 2006). Our lab previously has demonstrated that PYY is significantly 
increased following interposition surgery in euglycemic chow-fed rats (Strader AD 2008). But in 
the present study we observed a significant expression of PYY mRNA in the ileum of sham group 
whereas the interposition group showed lesser expression of PYY mRNA when compared to the 
sham group. 
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Figure 3.1: Intestinal GLUT2 mRNA expression in Sham (n=9) and Interposition (n=8) 
rats 6 months following interposition. Results are expressed as mean ± SEM, *p<0.01. 
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Figure 3.2: Liver GLUT2 mRNA expression in Sham (n=9) and Interposition (n=8) rats 
6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 3.3: Kidney GLUT2 mRNA expression in Sham (n=9) and Interposition (n=8) rats 
6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 3.4: Pancreatic GLUT2 mRNA expression in Sham (n=9) and Interposition (n=8) 
rats 6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 3.5: Hypothalamic GLUT2 mRNA expression in Sham (n=9) and Interposition 
(n=8) rats 6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 3.6: Intestinal PCK1 mRNA expression in Sham (n=9) and Interposition (n=8) rats 
6 months following interposition. Results are expressed as mean ± SEM, *p<0.05. 
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Figure 3.7: Kidney PCK1 mRNA expression in Sham (n=9) and Interposition (n=8) rats 6 
months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 3.8: Pancreatic PCK1 mRNA expression in Sham (n=9) and Interposition (n=8) 
rats 6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 3.9: Liver PCK1 mRNA expression in Sham (n=9) and Interposition (n=8) rats 6 
months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 3.10: Intestinal PYY mRNA expression in Sham (n=9) and Interposition (n=8) rats 
6 months following interposition. Results are expressed as mean ± SEM, *p<0.05, *p<0.01, 
*p<0.001. 
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Figure 3.11: PYY mRNA expression in different ileal segments (Sham-Ileum, Interposed 
Ileum and Remnant Ileum) in Sham (n=9) and Interposition (n=8) rats 6 months following 
interposition. Results are expressed as mean ± SEM, *p<0.05, **p<0.05. 
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Figure 3.12: Liver PYY mRNA expression in Sham (n=9) and Interposition (n=8) rats 6 
months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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CHAPTER 4 
SODIUM-GLUCOSE TRANSPORTER-1 (SGLT-1) 
 
Introduction 
 
 Disproportionate blood-glucose concentrations have a negative effect known to as 
glucotoxicity which can result in renal failure, neuropathy, and cardiac diseases (Kaiser N et al 
2003). As glucose is the central controller of insulin secretion and its production, larger amount 
of glucose over an expanded period has harmful effects on the pancreatic beta cell function, 
following-on to increased glucose sensitivity (Kahn BB et al 1992).  
 
As a result, blood-glucose concentrations must be sustained at stable point. Since the 
lipid bilayer of the plasma membrane is impermeable to hydrophilic molecules, glucose is 
carried across the membrane by membrane associated carrier proteins, glucose transporters 
(Joost H-G et al 1994; Wood S et al 2003). There are two special types of transporters, mediate 
the transfer of glucose and other related sugars through the lipid bilayer, a Na⁺-coupled carrier 
system (SGLT1) and the facilitative glucose transporters (GLUT). Both forms of transporters 
belong to the solute carrier family (SLC) include 43 families and 298 genes altogether 
(Carruthers A et al 1990; Wood S et al 2003). 
 
Glucose transporters of the SGLT and GLUT family are vital regulators of glucose 
utilization and storage. In addition to this, also is the part of glucosensing systems. Together their 
diversity allocates an explicit coordinated regulation of glucose transport activity being found on 
variable expression (Scheepers A et al 2004). 
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Hypothesis and Specific aim 
 
 
Expression of Sodium-dependent glucose transporter-1 (SGLT1) in gluconeogenic organs 
(Intestine and Kidney), and pancreas may show the importance of SGLT1/GLUT2 channel 
required to control postprandial glucose. Thereby, determine the expression of SGLT1 receptor 
in gluconeogenic organs (Intestine and Kidney), and pancreas using qPCR following sham and 
ileal interposition surgery. 
 
Materials and Methods 
 
 Non-diabetic male Long Evan’s rats (490-600g) (Harlan, Indianapolis, IN) fasted 
overnight (16 hours) and were anesthetized with isoflurane gas and received either a sham 
surgery or ileal interposition surgery. Following a period of 6 months after the surgeries, the rats 
were euthanized and various tissues were collected for different experiments. Brains were 
rapidly removed and gluconeogenic organs (Liver, Small intestine and Kidney), pancreas were 
placed in RNA later and stored at 4°C and then at -80°C until RNA were isolated. Hypothalami 
were dissected from the brains. SGLT1 expression in these organs was quantified using qPCR 
and compared to the housekeeping gene L32. Data were subjected to a one-way analysis of 
variance and post-hoc test called Newman-Keuls Multiple Comparison test was used with 
respect to the surgery received.  
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Results 
 
 
The expression of SGLT1 mRNA (% change relative to L32) in the sham surgery group 
articulated a significant difference between jejunum and colon. Jejunum increased by 2 folds in 
the expression of SGLT1 when compared to interposition group within the intestine (one-way 
ANOVA; p<0.05, Figure 4.1). SGLT1 mRNA (% change relative to L32) expression in the 
“interposed ileum” experienced a 30 fold increase when compared to sham surgery group. When 
the segments of intestines were compared individually to one another, the data were found to be 
insignificant (one-way ANOVA; p>0.05, Figure 4.1) leaving only colon against jejunum as a 
major change.   
 
Within the pancreas, the interposition group exhibited a 30% reduction in the SGLT1 
mRNA (% change relative to L32) compared to sham group and demonstrated no significant 
difference between the two surgical groups (Unpaired t-test; p>0.05, Figure 4.2). In kidney, the 
SGLT1 mRNA (% change relative to L32) expression remained unaltered in both the surgical 
groups and displayed a 50% decrease in the ileal interposition group (Student’s t-test; p>0.05, 
Figure 4.3). 
 
 
Discussion 
 
 
A study done last year shed light on the importance of SGLT1/GLUT2 channel required 
to control postprandial glucose within the small intestine and the kidney. For these purpose 
SGLT1 knockout mice were produced (Gorboulev V, Schürmann A et al 2011). Small intestinal 
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glucose absorption across the brush-border membrane (BBM) through SGLT1/GLUT2 channel 
was analyzed. Glucose-induced secretion of insulinotropic hormone (GIP) and glucagon-like 
peptide 1 (GLP-1) in wild-type and SGLT1 knockout mice were evaluated (Gorboulev V, 
Schürmann A et al 2011). 
 
It was evaluated that SGLT1 knockout mice increase the chances of getting a glucose-
galactose malabsorption syndrome but thrive usually when fed a glucose-galactose–free diet. In 
the wild-types, the channel of glucose across the intestinal BBM was chiefly arbitrated by 
SGLT1, free of any excess glucose present. Higher concentrations of glucose increased the 
amounts of SGLT1 and GLUT2 in the BBM, and SGLT1 was essential for GLUT2 upregulation 
(Gorboulev V, Schürmann A et al 2011).  
 
In the kidney, SGLT1 reabsorbed approximately 3% of the filtered glucose below the 
normal glycemic state. The study also indicated that SGLT1 is plays a fundamental function for 
intestinal mass absorption of glucose and triggers both the up regulation of GLUT2 the glucose-
induced secretion of GIP and GLP-1 (Gorboulev V, Schürmann A et al 2011). 
 
In an old qPCR study it was found that the expression of SGLT1 in the GI tract appears 
to be augmented in the small intestinal region’s duodenum, jejunum, and ileum; whereas this 
gene is expressed at minor level in the large intestine cecum (in rats), colon, as well as in other 
parts of the GI tract such as stomach and esophagus (Chen J, Williams S et al 2010). Conversely, 
SGLT4 has an exclusively moderate expression level in pancreas compared with SGLT1. In all 
other tissues tested, SGLT1 have a generally low level of expression (Chen J, Williams S et al 
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2010). In the present study also, we observed a similar outcome in case of the pancreas, the 
expression of SGLT1 was found lower when compared to the intestine and kidney. 
 
The expression of several sugar transporters in individual cells and tissues is a reflection 
of the different characteristics of the various transporters which are required to transport glucose 
across the membrane to the blood stream. These transporters provide a high degree of specificity 
in order to control the glucose uptake under different physiological conditions such as the state 
of hyperglycemia (Shepherd et al 1992).  
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Figure 4.1: Intestinal SGLT1 mRNA expression in Sham (n=9) and Interposition (n=8) 
rats six months following interposition. Results are expressed as mean ± SEM, *p<0.05, 
*p>0.05. 
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Figure 4.2: Pancreatic SGLT1 mRNA expression in Sham (n=9) and Interposition (n=8) 
rats 6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 4.3: Kidney SGLT1 mRNA expression in Sham (n=9) and Interposition (n=8) rats 
6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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CHAPTER 5 
PROTEIN EXPRESSION 
Introduction 
 
 
 In the postprandial conditions, moving sugars are rapidly taken up, metabolized and 
stored in the tissues. On the contrary, between meals, stored sugars are broken down to avoid any 
hypoglycemic conditions (Bell GI et al 1990). Glucose homeostasis varies on the capacity of the 
tissues to spot the indication of scarcity to build and mobilize the sugar storage (Wright EM et al 
2003). Interestingly, the intestine, pancreas, kidney and liver play a vital role in glucose 
regulation and hence express GLUT2, which is able to process high sugar concentrations 
competently. GLUT2 is abundant and its transfer action is not restricted to any physiological 
circumstances (Fukumoto H et al 1989; Thorens B et al 1990). 
 
 A steady monitoring of blood glucose concentrations by definite glucosensing means is 
essential for the continuation of the entire body glucose regulation (Thorens B et al 2003). The 
greatest glucose detection takes place in the pancreatic beta cells, which control insulin secretion 
(Postic C et al 2001). This sensor includes GLUT2, the enzyme glucokinase and ATP-sensitive 
K⁺ channel. When the glucose concentration in the extracellular matrix is augmented, extra 
glucose enters the beta cells through the low affinity GLUT2 transporter (Seino S et al 2000).   
 
Hypothesis and Specific aim 
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GLUT2 which is a primary glucose GI transporter may be required for glycemic 
improvement following ileal interposition. Therefore, determine the protein expression of 
GLUT2 in all sections of the small intestine and pancreas using Immunohistochemistry. 
 
Materials and Methods 
 
 
 Non-diabetic Long Evans rats (490-600g) underwent sham or ileal interposition surgery. 
Animals were fasted overnight (16 hours) and then euthanized to collect various organs and 
tissues for experimental reasons. Segments of duodenum, jejunum, ileum, colon, “interposed” 
ileum, remnant ileum and pancreata from both the surgical groups were fixed in Bouin’s solution 
for immunohistochemistry purposes. Later these tissues were sectioned at 5 μm and waxed to 
place them on a slide. Immunohistochemistry using polyclonal goat antibodies against GLUT2 
were used to visualize the protein expression within the intestinal segments and pancreata. 
Photomicrographs (Bright field microscope) of the sections from individual segments were taken 
at both 10X and 20X which were used for determining the GLUT2 expression in the pancreas 
and the apical membrane of the intestinal segments. Student’s t-test was used to determine 
statistical significance (p<0.05) between the surgical groups. 
 
 
Results 
 
 
The apical membrane within each of the intestinal segments was positive for GLUT2 
immunoreactivity.  We found specific differences in the amount of GLUT2 immunoreactivity in 
all the intestinal segments with respect to their orientation as small intestine in the ileal 
interposition and Sham surgery rats (Student’s t-test, p<0.05, Figure 5.1). The results of 
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immunohistochemistry were considered as a counterpart of the results obtained from qPCR. Our 
qPCR results verified the expression of GLUT2 to be chief in duodenum, jejunum and 
“interposed ileum” and minor expression in ileum (Sham), remnant ileum (Interposition) and 
colon when compared to the other segments. There was also a trend observed for greater GLUT2 
expression in the interposition males than sham males (Figure 5.2). 
 
Immunohistochemistry results for pancreatic islet cells; we observed extreme expression 
of GLUT2 in the islet cells in the sham when compared to the interposition. (Figure 5.3) The 
staining was nearly uniformly negative for GLUT2 in the pancreatic islet cells in the 
interposition (Figure 5.3). There was occasional weak GLUT2-positive staining in scattered 
islets in the sham (Figure 5.4). In contrast, the interposition group observed diffusely strong and 
positive staining in some of the islet tissue (Figure 5.4) and mostly the staining was weak in the 
islet tissue. 
 
 
 
Discussion 
 
Apical GLUT2 is gets activated by any diet with higher sugar levels; insertion is quickly 
stimulated by plain dietary sugars, and the apical GLUT2 unit of absorption is quite a few times 
better than the active substrate at high glucose concentrations (Shepherd EJ, Helliwell PA et al 
2004). Apical GLUT2 is firmly regulated by long and short term delivery of dietary sugars and 
also by the endocrine hormones, cellular energy condition and diabetes (Marks J et al 2003). As 
a result, apical GLUT2 provides a chief direction to sugar absorption by which the capacity of 
absorption is hastily upregulated to equal the dietary ingestion of sugars (O’Donovan DG, Doran 
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S et al 2004). Apical GLUT2 presents a safety feature by putting off the high sugar masses from 
arriving at the colon. Besides, the resultant quick delivery of sugar into the blood stream might 
also enhance the postprandial expeditions (Cheeseman CI 2002). 
 
 In this experiment, we found significant differences in the expression of GLUT2 in the 
apical membrane of the different intestinal segments between surgical groups. It appears that 
GLUT2 expression could remain constant following sham surgery but the expression could vary 
in areas such as the “interposed ileum” following interposition since the “interposed ileum” gets 
jejunalized and takes up the functions of jejunum. When we compared ileum of a sham rat to that 
of the interposition (remnant ileum), the expression of GLUT2 remains similar. Colon 
demonstrated no expression of GLUT2 in its apical membrane in both sham and interposition. 
Our observations were limited to the apical membrane of the intestinal segments, the only area 
where the expression of GLUT2 is highest in the intestine. 
 
The signal for glucose induced insulin secretion in pancreatic beta cells is generated in its 
metabolism (Meglasson MD 1984). The signal recognition apparatus is composed of low affinity 
glucose transporter GLUT2 (Thorens B 1988; Bell GI 1990). Glucose is reported to be a 
physiological regulator of the glucokinase enzyme activity in the pancreatic beta cells. Basically 
starvation reduces and refeeding normalizes the GLUT2 expression in the pancreatic beta cells 
(Iynedijian PB 1987; Tiedge M 1991).  
 
A previous study in Germany explained the reciprocated function of glucose and insulin 
in nutrient dependent regulation of glucokinase and GLUT2 gene expression in pancreatic beta 
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cells. They fed starved rats with glucose or glibenclamide, a drug antagonizing insulin secretion. 
The results perhaps illustrated that in pancreatic beta cells, glucose being useful and indicating 
the necessity of glucose to facilitate stimulation the expression of GLUT2 (Tiedge M, Lenzen S 
et al 1995). In another previous study the results showed that a loss of GLUT2 expression is a 
distinctive feature of glucose-unresponsive beta cells from diabetic animals. The study also 
depicted that the reduced expression is reversible and is the result of the diabetic environment 
(Thorens B 1992). 
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Figure 5.1: 10X photomicrograph of Slc2a2 (dark brown on the apical membrane) 
immunopositive reaction on Duodenum and Jejunum respectively after Sham surgery  
Slc2a2 
Slc2a2 
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Figure 5.1: 10X photomicrograph of Slc2a2 (dark brown on the apical membrane) 
immunonegative reaction on Ileum and Colon respectively after Sham surgery.  
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Figure 5.2: 10X photomicrograph of Slc2a2 (dark brown on the apical membrane) 
immunopositive reaction on Duodenum and Jejunum respectively after Interposition surgery.  
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Figure 5.2: 10X photomicrograph of Slc2a2 (dark brown on the apical membrane) 
immunopositive reaction on “Interposed ileum”and immunonegative reaction on Colon 
respectively after Interposition surgery.  
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Figure 5.2: 10X photomicrograph of Slc2a2 (dark brown on the apical membrane) 
immunonegative reaction on “Remnant” Ileum after Interposition surgery.  
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Figure 5.3: 10X photomicrograph of Slc2a2 on Pancreas (dark brown islet cells) immunopositive 
reaction after Sham Surgery and immunonegative reaction after Interposition surgery 
respectively. 
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CHAPTER 6 
POMC, AgRP AND NPY mRNA EXPRESSION  
 
Introduction 
 
 
 Glucose plays a vital role in energy homeostasis by regulating the secretion of a wide 
range of hormones and the establishment of neuronal circuits that control feeding and energy 
expenditure (Mobbs CV et al 2004; Marty N et al 2007). Sites of glucose detection are associated 
with the enteric nervous system, the hepatoportal vein region, the brain stem and hypothalamus 
(Marty N et al 2007). In the central nervous system, glucose sensing neurons falls into the two 
groups; glucose excited neurons and glucose inhibited neurons. These glucose sensitive neurons 
are found in the hypothalamic nuclei and the brain stem (Yang XJ et al 2004; Wang R et al 
2004). 
 
The melanocortin system is an association of neuronal networks inside the brain that 
amalgamates peripheral energy signals, afferent neuronal stimulation, and various advanced 
order inputs to regulate energy balance. The center of this system is centrally located in the 
mediobasal hypothalamus, specifically, the arcuate nucleus (ARC) (Mountjoy, et al. 1994; Wu, 
et al. 2002). Specifically, the neurons expressing pro-opiomelanocortin (POMC) or agouti-
related peptide (AgRP) and neuropeptide Y (NPY) in the arcuate 3 nucleus of the hypothalamus, 
downstream goals of POMC and AgRP neurons expressing melanocortin receptors (MC3R and 
MC4R), and hindbrain POMC neurons residing in the nucleus of the solitary tract are the 
principal components of the central melanocortin system (Cone 2005). 
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Hypothesis and Specific aim 
 
 
Hypothalamic genes known to regulate glucose homeostasis may be altered in rats with       
improved glucose tolerance following ileal interposition. Therefore, determine the expression of 
POMC, AgRP and NPY in the hypothalamus of rats following sham and ileal interposition 
surgery.  
 
 
Materials and Methods 
 
Non-diabetic male Long Evan’s rats (490-600g) (Harlan, Indianapolis, IN) fasted 
overnight (16 hours) and were anesthetized with isoflurane gas and received either a sham 
surgery or ileal interposition surgery. Following a period of 6 months after the surgeries, the rats 
were euthanized and various tissues were collected for different experiments. Brains were 
rapidly removed and Gluconeogenic organs (Liver, Small intestine and Kidney), pancreas were 
placed in RNA later and stored at 4°C and then at -80°C until RNA were isolated. Hypothalami 
were dissected from the brains. POMC, AgRP and NPY expression in the hypothalamus was 
quantified using qPCR and compared to the housekeeping gene L32. Data were subjected to a 
one-way analysis of variance and Newman-Keuls Multiple Comparison test was used with 
respect to the surgery received.  
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Results 
 
The expression of POMC mRNA (% change relative to L32) the both the surgical groups 
articulated no significant difference and the interposition group witnessed a 1% increase in the 
POMC mRNA expression in the hypothalamus (Unpaired t-test; p>0.05, Figure 6.1).  
 
The expression of AgRP mRNA in the hypothalamus (% change relative to L32) 
remained at no significance between the two surgical groups and again in the interposition group 
we observed the expression of AgRP mRNA increasing by 10% (Unpaired t-test; p>0.05, Figure 
6.2). The expression of NPY mRNA in the hypothalamus (% change relative to L32)  displayed a 
significant difference between the two surgical groups and yet again in the interposition group 
we observed the expression of NPY mRNA increasing by 2 folds (Unpaired t-test; p<0.05, Figure 
6.3).  
 
 
Discussion 
 
In the arcuate nucleus (ARC) of the hypothalamus consequently, two neuronal 
inhabitants are accountable for adding peripheral signals and altering energy homeostasis. Cells 
in the medial ARC articulate the orexigenic neuropeptides agouti related peptide (AgRP) and 
neuropeptide Y (NPY) and neurons inside the lateral arcuate nucleus articulate Pro-
opiomelanocortin (POMC) (Mountjoy and Wong 1997). POMC is a pre-prohormone that is 
chiefly localized in the brain, pituitary, and skin. Post-translational cleavage of POMC produces 
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several smaller molecules that are ligands to the melanocortin receptors (Hadley and Haskell-
Luevano 1999). 
 
POMC knockout mice are obese and add their weight is due to an increase in food intake 
or short of melanocortin tone by alpha-MSH (Yaswen, et al. 1999). These mice also undergo an 
augmented sensitivity to a high-fat diet (Butler, et al. 2001). In the brain, AgRP is formed 
entirely in the medial ARC and periaquaductal grey area (Broberger and Hokfelt 2001). AgRP 
neurons are 99% co-localized with neuropeptide Y (NPY) (Hahn, et al. 1998). On the contrary, a 
single intracerebroventricular (ICV) injection of AgRP produces an extended period of 
hyperphagia (Goodin, et al. 2008; Hagan, et al. 2000).  
 
Glucose sensing neurons in the hypothalamus have been implicated in the control of 
feeding behavior and glucose homeostasis and have been a topic for research in recent since they 
provide novel targets for the treatment of diabetes and obesity(O’Malley D et al 2006). GLUT2 
is expressed at low levels in the brain, and its localization using in situ hybridization techniques 
has yielded conflicting data in studies done previously. However, the general agreement is that 
the transporter is expressed by the neurons and glial cells in many brain regions (Gong S et al 
2007). Another study demonstrated that GLUT2 dependent glucose sensing is an important 
factor to control thermoregulation. This glucose signal may originates from GLUT2 expressing 
neurons located in the brain stem and sends projections to NPY and POMC neurons for proper 
regulation of energy homeostasis (Mounien L, Marty N et al 2010). 
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A study conducted record POMC, AgRP and NPY mRNA levels obese rats against the 
lean one stated that fasting significantly increased AgRP and NPY, and decreased POMC mRNA 
levels (Korner J, Savontaus E et al 2001). In the present study, we observed similar responses 
with respect to NPY and POMC mRNA’s. We observed a significant increase in the NPY mRNA 
expression in the ileal interposition which is supported by the fact that the rats were fasted (16 
hours) before euthanizing. 
 
Within the hypothalamus, NPY is an essential controller of body weight by its effects on 
food intake and energy expenditure. NPY operates on five different receptors (Y1-Y5 receptors), 
even though NPY emerges to put forth its orexigenic effect principally through the Y1 and Y5 
receptors, the preponderance of neurons expressing NPY in the hypothalamus are originated 
within the ARC and the majority co-express AgRP (Bagnol D et al 1999; Broberger C 1998). 
Decrease in NPY/ AgRP neurons in mice condenses food ingestion and body weight (Bewick GA 
et al 2005) even though in adult rats, ICV injection of NPY potently excite food intake (Clark JT 
1984).  
 
The pre-pro-glucagon (PPG) gene is broadly expressed in the enteroendocrine L cells of 
the intestine, pancreas and brainstem. It is sliced by pro-hormone convertases 1 and 2 to produce 
mainly glucagon in the pancreas, and GLP-1, GLP-2 and oxyntomodulin in the central nerous 
system and intestine. GLP-1 is released into the blood stream following a meal in the ratio to the 
calories consumed and proceeds through the vagus nerve to restrain the food intake (Turton MD 
1996). GLP-1 receptor mRNA is compactly expressed in the ARC and over 60% emerges out to 
be co-localized with POMC neurons (Sandoval DA et al 2008).  
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PYY (Peptide YY) is released by L-cells in the GI, into the blood circulation subsequent 
to a meal. Peripheral administration of PYY is found to reduce food intake in rodents and humans 
and PYY knockout mice develop obesity (Boey D et al 2006; Asakawa A et al 2003). Even 
though the accurate mechanisms are vague, the anorectic effects of PYY are believed to happen 
through the Y2 receptor since this is eradicated in Y2 receptor knockout mice (Batterham RL et 
al 2002). The Y2 receptor is extremely articulated on ARC NPY neurons and PYY may reduce 
food intake by reducing NPY discharge through auto inhibitory Y2 receptors (Batterham RL et al 
2002).  
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Figure 6.1: Hypothalami POMC mRNA expression in Sham (n=9) and Interposition 
(n=8) rats 6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 6.2: Hypothalami AgRP mRNA expression in Sham (n=9) and Interposition (n=8) 
rats 6 months following interposition. Results are expressed as mean ± SEM, *p>0.05. 
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Figure 6.3: Hypothalami NPY mRNA expression in Sham (n=9) and Interposition (n=8) 
rats 6 months following interposition. Results are expressed as mean ± SEM, *p<0.05. 
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CHAPTER 7 
SUMMARY AND CONCLUSIONS 
 
 
Diabetes is a widespread chronic disease and an emerging global epidemic. For the year 
2010, the number of individuals affected with type 2 diabetes was approximately 300 million and 
this number is projected to raise 54% by 2030 (Danaei et al 2011). Patients with type 2 diabetes 
have an increased risk of complications, which are considerable cause of morbidity and 
mortality, including neuropathy, cardiac diseases and nephropathy (Calcutt NA 2009). 
Treatments were primarily based on substantial lifestyle changes, diet modification and physical 
activity. In most of the patients, these behavioral measures were not adequate to keep up a good 
glycemic index and in due course oral anti-diabetic agents were also added (Stolar MW 2008). 
 
In addition to the wide variety of pharmacological options for weight loss and glycemic 
control, bariatric and metabolic surgeries were also included among the therapeutic approaches 
to type 2 diabetes and insulin resistance (Czupryniak L 2010; Rubino F 2002). Bariatric surgery 
eventually became a common way of treating weight loss and a 9 fold increase was observed in 
the number of bariatric surgeries performed annually in the United States. Bariatric surgery also 
displayed an improvement in co-morbid conditions like heart diseases, dyslipidemia and type 2 
diabetes and most importantly, the 5 year mortality rates were reduced in about 90% patients 
receiving bariatric surgery.  
 
Surgeries like Roux-en-Y gastric bypass favor the stimulation of GLP-1 producing L-
cells by the arrival of food at the distal portions of the small intestine stating a hypothesis that 
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distal intestine might be playing an essential role in order to achieve significant weight loss. To 
clarify the understanding the importance and the vital role played by the lower intestine, we used 
ileal interposition as a model in rats. In our model, we moved a 10cm distal intestine called ileum 
to upper intestine in between the duodenum and jejunum. The effects of GLP-1 secretion and 
glucose tolerance were observed in most of our previous models and this particular model also 
we observed a similar outcome in rats. We collected different intestinal segments and other 
tissues for experiments like real time PCR (qPCR) and protein expression 
(immunohistochemistry) and observed the expression of certain receptors and their modifications 
in gluconeogenic organs. 
 
In the qPCR results, we found the expression of GLUT2 mRNA in the ileal interposition 
increased by 8 folds in the “interposed ileum” segment when compared to the sham surgery 
within the intestine. In the pancreas, the interposition group exhibited a 40% reduction in the 
GLUT2 mRNA expression when compared to sham group, demonstrating no significant 
difference between the two surgical groups. In kidney, the GLUT2 mRNA expression again 
remained unaffected in both the surgical groups. The expression of PCK1 mRNA displayed a 3 
fold increase in the “interposed ileum” segment within the intestine. In kidney, the PCK1 mRNA 
expression viewed a 70% reduction in the interposition group when compared to the sham. 
Within the pancreas, the interposition group exhibited a 1% increase in the PCK1 mRNA.  
 
The expression of PYY mRNA increased 5 folds when colon and duodenum were 
compared to one another. PYY mRNA expression in the liver remained unchanged between the 
two surgical groups. The expression of SGLT1 mRNA in the sham surgery group articulated a 
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significant difference between jejunum and colon. SGLT1 mRNA expression in the “interposed 
ileum” experienced a 30 fold increase when compared to sham surgery group. Within the 
pancreas, the interposition group exhibited a 30% reduction in the SGLT1 mRNA. In kidney, the 
SGLT1 mRNA expression remained unchanged. 
 
The expression of POMC mRNA increased 1% in the interposition group when compared 
to sham. The expression of AgRP mRNA in the hypothalamus increased 10% in the ileal 
interposition group when compared to sham. The expression of NPY mRNA in the hypothalamus 
displayed a 2 fold increase in the interposition group. The immunohistochemistry results 
displayed similar results when compared to the qPCR results. The expression of GLUT2 was 
observed in the different segments of the intestine and pancreatic islet cells. 
 
To conclude the final findings: SGLT1 and GLUT2 expression increased in the 
“interposed” ileum significantly in comparison to other intestinal segments. Protein expressions 
of GLUT2 in the intestinal segments were similar to that of the qPCR results. Pancreatic GLUT2 
expression significantly decreased in ileal interposition, quantifying the qPCR results. NPY is an 
essential controller of body weight by its effects on food intake and energy expenditure and 
increases during fasting. The SGLT1/GLUT2 channel work effectively to control the 
postprandial glucose. 
 
UNANSWERED QUESTIONS: FUTURE DIRECTION 
 
GLUT2 is also expressed in central nervous system and requires autonomous nervous 
system to arbitrate hepatoportal glucose sensing (Leloup et al 1994). Conversely, glucose enters 
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the epithelial cell through the sodium glucose transporter (SGLT-1) and is released into the 
mesenteric blood via GLUT2 (Turk et al 1991). This could suggest that GLUT2 dependent 
enteric glucose absorption is not the main regulatory mechanism for glucose sensing. A 
corresponding set of data also propose that carbohydrate receptors are found in the lumen of the 
intestine (Dyer et al 2003). Surprisingly, the intestinal GLP-1 content is reduced in GLUT2 and 
GIP receptor knockout but not GLP-1 receptor knockout mice. This shows the significance of 
these molecular mechanisms for the regulation of GLP-1 synthesis which could contribute in part 
to the impaired secretion of the hormone (Pederson et al 1998).  
 
This could be a great field to spread our knowledge since glucose homeostasis is very 
important and should be balanced to maintain a steady glucose rate in the blood stream. We think 
that oral glucose tolerance test on non-diabetic rats after ileal interposition may have some 
answers with respect to the maintenance of percent basal glucose. We also think that the co-
localization of SGLT-1 and GLUT2 in the gluconeogenic organs may also lead to some 
interesting data. Since, now as we know that SGLT-1 and GLUT2 work together to transport 
glucose across the lumen efficiently, it would be interesting to observe the expression of both the 
receptors together on the gluconeogenic organs especially the small intestine. This would be 
possible if a proper protocol for immunohistochemistry is set so that the co-localization of the 
two receptors would be known. 
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